OS Therapies: OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
OS Therapies (NYSE American: OSTX) announced that the World Health Organization approved 'Herlystic' as the brand name for OST-HER2, a gene-edited cancer immunotherapy. The company plans to initiate regulatory submissions for early market access in the U.K., U.S., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, and the company aims to file for a Biologics License Application in the U.S. in 2026.
How this was made
The 30-second read
Why it matters
The approval removes a branding barrier, allowing the company to pursue accelerated regulatory pathways and potential PRV sales, which could materially affect valuation.
Market read
First‑time disclosure of WHO brand name approval creates a new catalyst for OSTX, potentially driving short‑term price movement and long‑term valuation.
What to watch
Potential competition from other HER2 therapies and the need for robust Phase 3 data.
Background
OS Therapies announced WHO brand name approval for its lead asset OST-HER2 and outlined upcoming submissions to MHRA, FDA, EMA, and TGA.
Ticker impact
WHO approved the brand name 'Herlystic' for OST-HER2, enabling OS Therapies to begin international regulatory submissions.
Modest short‑term rally on news, with larger upside if filings succeed.
First disclosure of brand name approval and clear regulatory roadmap creates new catalyst for the stock.
Market effects
Highlights progress in gene‑edited Listeria immunotherapy, may boost biotech sector sentiment.
UK and US regulatory activity could attract investor interest in those markets.
WHO brand name approval is globally relevant for oncology drug pipelines.
Counterpoint
Regulatory hurdles remain; early filings do not guarantee approval, risk of delays.
Key entities
- companyOS Therapies, Inc.
Clinical‑stage oncology company developing gene‑edited Listeria‑based immunotherapies.
- regulatory_bodyWorld Health Organization
International health agency that approved the brand name.
